Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
Rabies Immunoglobulin Recall Follows Potency Stability Failure
A UK recall of Human Rabies Immunoglobulin after reduced potency highlights how stability failures can become urgent safety and effectiveness issues.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
FDA’s Action on Xylazine Imports Shows How Safety Oversight Extends Beyond Approved Drugs
FDA’s restrictions on unlawful xylazine imports are a reminder that safety oversight can extend well beyond approved medicines and labeled use.
PRAC Reviewed 140 PSUR Recommendations in January 2026: What That Tells Us
EMA’s January 2026 PRAC statistics offer a useful reminder that much of pharmacovigilance is steady, high-volume regulatory review rather than dramatic safety headlines.
Why EMA’s MSSG Matters When Shortages Become Safety Issues
EMA’s MSSG shows how supply, quality, safety, and crisis oversight increasingly overlap when shortages escalate.
CTIS Sponsor Training in June 2026 Signals the Growing Importance of Trial-System Skills
EMA’s June 2026 CTIS sponsor training programme shows that system literacy is becoming a bigger part of clinical-trial and safety-readiness expectations.
EMA’s PMS FAQs Show Where Product Data Friction Still Exists
EMA’s PMS FAQ document gives a useful look at where product-data workflows still create uncertainty for users in regulated digital environments.
MHRA’s National Assessment Procedure Update: Why It Matters in 2026
MHRA’s updated national assessment procedure guidance is another reminder that UK regulatory pathways are still evolving and still matter to PV-adjacent teams.
Featured Posts
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s February 2026 Safety Roundup is a useful reminder that regulators are increasingly packaging practical safety advice in faster, easier-to-scan formats.
MHRA’s National Assessment Procedure Update: Why It Matters in 2026
MHRA updated its national assessment procedure guidance in February 2026, another reminder that UK regulatory pathways are continuing to evolve post-Brexit and post-Windsor.
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s February 2026 Safety Roundup is a useful reminder that regulators are increasingly packaging practical safety advice in ways teams can scan and act on quickly.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contact us
Email Us
editor@pvwatchdaily.com